Interaction between Methyldopa and Methylene blue
Major
Synergy
| ID | DDInter1185 and DDInter1186 |
| Interaction | Coadministration of methyldopa and monoamine oxidase inhibitors (MAOIs) may result in loss of blood pressure control and/or signs of central stimulation such as hyperexcitability and hallucinations. The mechanism may involve excessive sympathetic stimulation in the central nervous system. |
| Management | Concurrent use of methyldopa with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine) is considered contraindicated. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with methyldopa. |
| References | |
| Alternative for Methyldopa | - |
| Alternative for Methylene blue |
V03A
More
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.